Advances in the Treatment of Non-Hodgkin’s Lymphoma: Exploring New Frontiers

A recent symposium at the European Hematology Association (EHA) congress, chaired by Prof Eva Kimby, explored the changing paradigms in the treatment of non-Hodgkin’s lymphoma (NHL) and the potential impact of new approaches to diagnosis and treatment. Prof Kimby opened the symposium by discussing the recent therapeutic advances in the treatment of follicular lymphoma (FL). Prof Georg Lenz then spoke about the clinical implications of diffuse large B cell lymphoma (DLBCL) diagnosis and the manner in which disease subtyping can foster effective use of targeted therapies. Prof Catherine Thieblemont presented on post-induction treatment in DLBCL, and the importance of effective treatment options to limit the number of patients who fail first-line therapy. Prof Pier Luigi Zinzani then concluded the symposium by presenting data on the new immuno-oncology treatments being evaluated in patients with relapsed or refractory NHL.